In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Mirati Therapeutics Inc. (NASDAQ:MRTX) reported that Boxer Capital, Llc. has picked up 1,340,537 of common stock as of 2017-06-27.
The acquisition brings the aggregate amount owned by Boxer Capital, Llc. to a total of 1,340,537 representing a 5.3% stake in the company.
For those not familiar with the company, Mirati Therapeutics Inc. (NASDAQ:MRTX) is at the forefront of precision medicine — developing genetically-targeted oncology therapeutics for carefully selected groups of patients most likely to benefit from treatment. Mirati’s approach to precision medicine combines three critical factors. Most importantly, Mirati’s drug candidates target specific genetic and epigenetic drivers of cancer. Mirati combines the therapeutic potential of these assets with its creative and agile clinical development strategies focused on identifying and treating patients whose tumors carry the drivers of disease. Finally, this process is led and executed by a highly accomplished precision medicine team, with a track record of bringing breakthrough therapies with accelerated development paths to market.
A glance at Mirati Therapeutics Inc. (NASDAQ:MRTX) key stats reveals a current market capitalization of $91.03 Million based on $24.94 Million shares outstanding and a price at last close of $3.70 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2017-01-26, Braslyn picked up 28,839 at a purchase price of $5.45. This brings their total holding to 2,880,702 as of the date of the filing.
On the sell side, the most recent transaction saw Baker unload 2,318 shares at a sale price of $9.56. This brings their total holding to 30,003.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an Mirati Therapeutics Inc. (NASDAQ:MRTX) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.